VK 5211

Drug Profile

VK 5211

Alternative Names: LGD 4033; VK-5211

Latest Information Update: 16 May 2017

Price : $50

At a glance

  • Originator Ligand Pharmaceuticals
  • Developer Viking Therapeutics
  • Class Small molecules
  • Mechanism of Action Selective androgen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hip fracture
  • Preclinical Cachexia
  • No development reported Hypogonadism; Muscular atrophy; Osteoporosis

Most Recent Events

  • 21 Mar 2017 Viking Therapeutics has patent protection and pending patent applications for thyroid hormone receptor beta agonists in USA, Europe, Chile, Argentina, Brazil, Canada, China, India, Japan, Korea, Mexico, Taiwan, and Venezuela
  • 01 Sep 2016 Adverse events and pharmacokinetics data from a phase I trial in Hip fracture released by Viking Therapeutics
  • 01 Sep 2016 Viking Therapeutics completes a phase I trial in Hip fracture in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top